A Phase 2 interventional study of Tislelizumab in Classical Hodgkin Lymphoma, sponsored by BeiGene. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.
Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 315th largest by enrollment of the 818 interventional ones that give a count, is one of 11 that started in 2020, is one of 346 in phase 2, and was the 866th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
Michael Spinner, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
970 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 389 · Phase 2 460 · Phase 3 57 · Phase 4 1
First in 1988; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 35 across the 818 interventional studies, 111 across the 80 observational. Of the 779 that completed or were terminated, 326 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 970 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 3 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
49 of the studies in Hodgkin Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01483664Memorial Sloan Kettering Cancer CenterCommunication Skills Intervention to Promote Transition Into Survivorship | 2026-11 |
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT06923397Dana-Farber Cancer InstituteInterrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | 2026-11-28 |
| NCT05723055University of UtahEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2026-12 |
| NCT06150664Compass TherapeuticsA Phase 1 of CTX-8371 in Patients With Advanced Malignancies | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 970 studies in Hodgkin Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.
Key Inclusion Criteria:
Participants had either:
Participants were assigned to one of two cohorts based on the following:
Cohort 1: Participants who were relapsed or refractory after prior hematopoietic stem cell transplantation (HSCT):
Cohort 2: Participants who were relapsed or refractory to salvage chemotherapy and had not received prior HSCT:
Key Exclusion Criteria:
Note: Additional inclusion and exclusion criteria defined in the protocol may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who had relapsed or refractory classical Hodgkin lymphoma and had either not achieved a response or had disease progression following autologous hematopoietic stem cell transplantation received tislelizumab 200 milligrams (mg) intravenously every 3 weeks.
Drug: Tislelizumab
Participants who had relapsed or refractory classical Hodgkin lymphoma and had either not achieved a response or had disease progression after at least one prior systemic therapy and were not candidates for autologous or allogeneic hematopoietic stem cell transplantation received tislelizumab 200 mg intravenously every 3 weeks.
Drug: Tislelizumab
200 milligrams (mg) intravenously every 3 weeks (Q3W)
Also known as: BGB-A317
Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) by Positron Emission Tomography (PET) and Computed Tomography (CT) per the Lugano Classification and as determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT, with no new lesions detected. PR was defined as a significant reduction in metabolic activity or lesion size consistent with partial tumor shrinkage as per Lugano criteria.
Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Complete Response Rate (CRR)
CRR was defined as the percentage of participants who achieved a best overall response of complete response (CR) by PET-CT or CT per the Lugano Classification and determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT or CT, with no new lesions detected.
Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Duration of Response (DOR)
DOR was defined as the time from the date that response criteria (CR or PR) were first met to the date of objectively documented disease progression or death, whichever occurred first. Participants without an event were censored at the data cutoff or end of study, whichever occurred first. Participants who received new anti-lymphoma therapies, including Hematopoietic Stem Cell Transplantation (HSCT), before having an event were censored at the date of therapy initiation. Only participants with confirmed response were included in the analysis. Median DOR was estimated using the Kaplan-Meier method.
Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Time to Response (TTR)
TRR was defined as the time from the date of the first dose of tislelizumab to the date the response criteria were first met CR or PR per the Lugano Classification, and was analyzed only in participants who achieved an overall response; CR was defined as complete disappearance of disease, PR as ≥50% reduction in tumor burden, and Overall Response Rate (ORR) included participants with either CR or PR.
Time frame: From first dose to primary analysis data cutoff (12 Dec 2022) or new anti-lymphoma therapy start, whichever came first. Median follow-up was 11.4 months.
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Treatment-emergent adverse events (TEAEs) were defined as any AE that began or worsened in severity after the first dose of study treatment and up to 90 days following the last dose, regardless of initiation of new anti-lymphoma therapy. The following safety data are reported: Number of participants with any TEAEs: Participants who experienced at least one TEAE of any grade. Number of participants with any Grade ≥3 TEAEs: Participants who experienced at least one TEAE that was Grade 3 or higher in severity. Number of participants with any SAEs: Participants who experienced at least one serious adverse event, regardless of relationship to study treatment, occurring up to 90 days after the last dose.
Time frame: From the date of the first dose of tislelizumab through 90 days after the last dose (maximum duration of tislelizumab exposure was 168 weeks)
This study was conducted at multiple centers across France, the United States, Belgium, and Australia from August 20, 2020, to August 29, 2024.
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 15 | 31 |
| Treated | 14 | 31 |
| Completed | 0 | 0 |
| Not completed | 15 | 31 |
| Withdrew: Study closed by sponsor | 10 | 22 |
| Withdrew: Death | 3 | 9 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 |
ORR was defined as the percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) by Positron Emission Tomography (PET) and Computed Tomography (CT) per the Lugano Classification and as determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT, with no new lesions detected. PR was defined as a significant reduction in metabolic activity or lesion size consistent with partial tumor shrinkage as per Lugano criteria.
| Percentage of Participants | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Overall Response Rate (ORR) | 64.3 (35.1 to 87.2) | 64.5 (45.4 to 80.8) | 64.4 (48.8 to 78.1) |
CRR was defined as the percentage of participants who achieved a best overall response of complete response (CR) by PET-CT or CT per the Lugano Classification and determined by the investigator. CR was defined as the complete disappearance of all target lesions on PET-CT or CT, with no new lesions detected.
| Percentage of Participants | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Complete Response Rate (CRR) | 42.9 (17.7 to 71.1) | 25.8 (11.9 to 44.6) | 31.1 (18.2 to 46.6) |
DOR was defined as the time from the date that response criteria (CR or PR) were first met to the date of objectively documented disease progression or death, whichever occurred first. Participants without an event were censored at the data cutoff or end of study, whichever occurred first. Participants who received new anti-lymphoma therapies, including Hematopoietic Stem Cell Transplantation (HSCT), before having an event were censored at the date of therapy initiation. Only participants with confirmed response were included in the analysis. Median DOR was estimated using the Kaplan-Meier method.
| months | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Duration of Response (DOR) | 12.25 (5.55 to 12.25) | 6.64 (2.79 to NA) | 12.25 (3.02 to NA) |
TRR was defined as the time from the date of the first dose of tislelizumab to the date the response criteria were first met CR or PR per the Lugano Classification, and was analyzed only in participants who achieved an overall response; CR was defined as complete disappearance of disease, PR as ≥50% reduction in tumor burden, and Overall Response Rate (ORR) included participants with either CR or PR.
| months | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Time to Response (TTR) | 2.69 (2.1 to 5.5) | 2.69 (0.3 to 5.6) | 2.69 (0.3 to 5.6) |
Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Treatment-emergent adverse events (TEAEs) were defined as any AE that began or worsened in severity after the first dose of study treatment and up to 90 days following the last dose, regardless of initiation of new anti-lymphoma therapy. The following safety data are reported: Number of participants with any TEAEs: Participants who experienced at least one TEAE of any grade. Number of participants with any Grade ≥3 TEAEs: Participants who experienced at least one TEAE that was Grade 3 or higher in severity. Number of participants with any SAEs: Participants who experienced at least one serious adverse event, regardless of relationship to study treatment, occurring up to 90 days after the last dose.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of participants with any TEAEs | 12 | 30 |
| Number of participants with any TEAEs with grade >= 3 | 4 | 12 |
| Number of participants with any SAEs | 4 | 9 |
Collected over All-cause mortality was reported from randomization to 29 Aug 2024 (4 years). AEs were reported from first tislelizumab dose to 90 days post-last dose (max exposure: 168 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 3/14 (21.4%) | 4/14 (28.6%) | 12/14 (85.7%) |
| Cohort 2 | 9/31 (29%) | 9/31 (29%) | 30/31 (96.8%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/14 | 0/31 |
| Lipase increasedInvestigations | 1/14 | 0/31 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/14 | 0/31 |
| Cutaneous t-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/14 | 0/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/14 | 0/31 |
| Coeliac diseaseGastrointestinal disorders | 0/14 | 1/31 |
| Chest painGeneral disorders | 0/14 | 1/31 |
| PyrexiaGeneral disorders | 0/14 | 1/31 |
| PeritonitisInfections and infestations | 0/14 | 1/31 |
| SepsisInfections and infestations | 0/14 | 1/31 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| AstheniaGeneral disorders | 1/14 | 9/31 |
| Influenza like illnessGeneral disorders | 3/14 | 0/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/14 | 5/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/14 | 3/31 |
| Dry skinSkin and subcutaneous tissue disorders | 3/14 | 2/31 |
| NauseaGastrointestinal disorders | 1/14 | 5/31 |
| DiarrhoeaGastrointestinal disorders | 2/14 | 2/31 |
| VomitingGastrointestinal disorders | 2/14 | 3/31 |
| FatigueGeneral disorders | 2/14 | 4/31 |
| BronchitisInfections and infestations | 2/14 | 3/31 |
The Safety Analysis Set included all participants who received at least one dose of study drug.
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 43.9 ± 15.78 | 59.6 ± 21.95 | 54.7 ± 21.37 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 4 | 11 | 15 |
| Male | 10 | 20 | 30 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| White | 3 | 5 | 8 |
| Not Reported | 11 | 26 | 37 |
| Patient Status at Time of Enrollment(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Refractory | 0 | 13 | 13 |
| Relapse/Progression | 14 | 18 | 32 |
| The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| 0 (Normal activities) | 10 | 18 | 28 |
| 1 (Ambulatory able to carry out work) | 4 | 13 | 17 |
| Number of prior lines of therapy for cHL(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| 1 | 0 | 7 | 7 |
| 2 | 9 | 17 | 26 |
| 3 | 4 | 6 | 10 |
| 4 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Aug 2020 to primary completion in Dec 2022, 27 months.
Results were first posted in Sep 2025, 2 years 9 months after primary completion. A results delay was requested in Dec 2023.
Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab